Considerations regarding an updated meta-analysis of the optimal duration of oxaliplatin-based adjuvant chemotherapy in patients with different risk factors for stage II-III colon cancer

被引：0
|
作者：
Pang, Huayang [1 ,2 ]
Yan, Menghua [1 ]
Chen, Lihui [1 ]
Zhao, Zhou [1 ,2 ]
Li, Wei [1 ]
Zhang, Shouru [1 ]
Sun, Hao [1 ]
机构：
[1] Chongqing Univ Canc Hosp, Dept Gastrointestinal Canc Ctr, Chongqing 400030, Peoples R China
[2] Chongqing Univ Canc Hosp, Chongqing Key Lab Translat Res Canc Metastasis & I, Chongqing, Peoples R China
来源：
INTERNATIONAL JOURNAL OF SURGERY | 2024年 / 110卷 / 07期
关键词：
FLUOROPYRIMIDINE; THERAPY;
D O I：
10.1097/JS9.0000000000001350
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：4431 / 4432
页数：2
相关论文
共 50 条
  • [41] Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.
    Shi, Qian
    Sobrero, Alberto F.
    Shields, Anthony Frank
    Yoshino, Takayuki
    Paul, James
    Taieb, Julien
    Sougklakos, Ioannis
    Kerr, Rachel
    Labianca, Roberto
    Meyerhardt, Jeffrey A.
    Bonnetain, Franck
    Watanabe, Toshiaki
    Boukovinas, Ioannis
    Renfro, Lindsay A.
    Grothey, Axel
    Niedzwiecki, Donna
    Torri, Valter
    Andre, Thierry
    Sargent, Daniel J.
    Iveson, Timothy
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (18)
  • [42] ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy
    Li, P.
    Fang, Y. J.
    Li, F.
    Ou, Q. J.
    Chen, G.
    Ma, G.
    BRITISH JOURNAL OF CANCER, 2013, 108 (06) : 1238 - 1244
  • [43] Patient Selection for Adjuvant Chemotherapy in High-Risk Stage II Colon Cancer A Systematic Review and Meta-Analysis
    Zhang, Chao
    Yin, Songcheng
    Tan, Yuen
    Huang, Jinyu
    Wang, Pengliang
    Hou, Wenbin
    Zhang, Zhe
    Xu, Huimian
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2020, 43 (04): : 279 - 287
  • [44] Real-world tolerance and outcomes of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer-Does dose intensity matter?
    Yoon, Robert
    Wilkinson, Kate
    Gabriel, Gabriel
    Kadaan, Nasreen
    Roberts, Tara
    Lim, Stephanie
    Asghari, Ray
    Lee, Cheok Soon
    Chua, Wei
    Ng, Weng
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2024, 20 (01) : 63 - 70
  • [45] Baseline creatinine clearance as an indicator of severe adverse events associated with oxaliplatin-based adjuvant chemotherapy in patients with stage III colon cancer: Safety analysis of the phase III Japanese ACHIEVE trial
    Nakamura, Masato
    Kotaka, Masahito
    Eto, Tetsuya
    Manaka, Dai
    Hasegawa, Junichi
    Takagane, Akinori
    Kato, Takeshi
    Munemoto, Yoshinori
    Nakamura, Fumitaka
    Bando, Hiroyuki
    Taniguchi, Hiroki
    Gamoh, Makio
    Shiozawa, Manabu
    Yamanaka, Takeharu
    Mizushima, Tsunekazu
    Sakamoto, Junichi
    Saji, Shigetoyo
    Ohtsu, Atsushi
    Mori, Masaki
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [46] Prognostic factors of adjuvant chemotherapy discontinuation among stage III colon cancer patients: A survey of medical oncologists and a systematic review and meta-analysis
    Boyne, Devon J.
    O'Sullivan, Dylan E.
    Heer, Emily, V
    Hilsden, Robert J.
    Sajobi, Tolulope T.
    Cheung, Winson Y.
    Brenner, Darren R.
    Friedenreich, Christine M.
    CANCER MEDICINE, 2020, 9 (05): : 1613 - 1627
  • [47] p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy
    Hyeon Jeong Oh
    Jeong Mo Bae
    Xianyu Wen
    Seorin Jung
    Younghoon Kim
    Kyung Ju Kim
    Nam-Yun Cho
    Jung Ho Kim
    Sae-Won Han
    Tae-You Kim
    Gyeong Hoon Kang
    British Journal of Cancer, 2019, 120 : 797 - 805
  • [48] p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy
    Oh, Hyeon Jeong
    Bae, Jeong Mo
    Wen, Xianyu
    Jung, Seorin
    Kim, Younghoon
    Kim, Kyung Ju
    Cho, Nam-Yun
    Kim, Jung Ho
    Han, Sae-Won
    Kim, Tae-You
    Kang, Gyeong Hoon
    BRITISH JOURNAL OF CANCER, 2019, 120 (08) : 797 - 805
  • [49] Assessment of the Addition of Oxaliplatin to Fluoropyrimidine-Based Adjuvant Chemotherapy in Patients With High-Risk Stage II Colon Cancer: An ACCENT Pooled Analysis
    Chibaudel, Benoist
    Raeisi, Morteza
    Cohen, Romain
    Yothers, Greg
    Goldberg, Richard M.
    Bachet, Jean-Baptiste
    Wolmark, Norman
    Yoshino, Takayuki
    Schmoll, Hans-Joachim
    Kerr, Rachel
    Lonardi, Sara
    George, Thomas J.
    Shacham-Shmueli, Einat
    Shi, Qian
    Andre, Thierry
    de Gramont, Aimery
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (35)
  • [50] Meta-analysis of oxaliplatin-based versus fluorouracil-based neoadjuvant chemoradiotherapy and adjuvant chemotherapy for locally advanced rectal cancer
    Fu, Xing-li
    Fang, Zheng
    Shu, Liang-hui
    Tao, Guo-qing
    Wang, Jian-qiang
    Rui, Zhi-lian
    Zhang, Yong-jie
    Tian, Zhi-qiang
    ONCOTARGET, 2017, 8 (21) : 34340 - 34351
12345